Moderna Stocks Surge as Melanoma Therapy Meets Phase 3 Goal
Moderna (MRNA) and Merck (MRK) announced Wednesday that their experimental melanoma therapy met the primary goal in a Phase 3 trial, with Moderna stocks nearly doubling in pre-market trading. The combination of Intismeran Autogene and Merck's Keytruda produced statistically significant
LucasBennett·8m ago
